Tavros is also leveraging its proprietary platform and map of useful synthetic lethal relationships to build a pipeline of small-molecule drug candidates. Strategic partnerships with Zentalis Pharmaceuticals, OpenBench, and Vividion Therapeutics have validated the platform and expanded the company’s clinical impact.
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze